Business
Xeris Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Updates
Gvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020 Gvoke HypoPen™ on track for planned launch in July 2020 Initiated programs to ensure
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":"\nGvoke™ Pre-Filled Syringe (PFS) net sales of $1.7 million in Q1 2020\n\n\nGvoke HypoPen™ on track for planned launch in July 2020 \n\n\nInitiated programs to ensure easier patient access to GVOKE in the midst of the COVID-19 pandemic\n\n\nCorporate actions taken to conserve cash\n\n\nConference call and webcast today at 8:30 a.m. ET\n\n CHICAGO--(BUSINESS WIRE)--\nXeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and infusible drug formulations, today announced financial results for the first quarter ended March 31, 2020, as well as pipeline and corporate highlights.\n\n\n“Starting in January with the field launch, Gvoke PFS began to see a very positive response from the diabetes community as evidenced by early and steady uptake of prescriptions, units, and units per prescription until the dynamics of the ongoing COVID-19 pandemic slowed our momentum. In response to the pandemic, we quickly moved to a virtual selling model and implemented several programs in an effort to minimize the impact of the crisis on the diabetes patient community and our business,” said Paul R. Edick, Chairman and CEO of Xeris. “The second quarter will be extremely busy as we work to drive Gvoke PFS prescription growth, prepare for the July launch of Gvoke HypoPen, and report topline results from three additional clinical programs.”\n\n\nFirst Quarter 2020 Highlights and Recent Events\n\n\nGvoke™\n\n\n‒ Xeris implemented and recently extended its $0 copay offer for Gvoke PFS to commercially insured patients to May 31, 2020 in response to the ongoing COVID-19 pandemic.\n\n\n‒ In March, Xeris instituted the Xeris Support Program - a HUB powered by ASPN, which offers support for healthcare professionals from benefits verification and prior authorization support (if needed) to free home delivery of Gvoke for the patient.\n\n\n‒ The Company is on track for its planned launch of Gvoke HypoPen, its liquid stable glucagon in an auto-injector for low blood sugar emergencies, in July 2020.\n\n\n‒ In May, the Journal of Medical Economics published a peer-reviewed paper entitled, “A ready-to-use liquid glucagon for treatment of severe hypoglycemia demonstrates reduced healthcare payer costs in a budget impact model” and can ...